Invitae Corp.

NVTA

$47.24

+161.98% (1 year change)

Avg closing price

Price range

Market Cap

$6.98 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$46.2 Million

Total revenue in the last quarter.

Net Income

$-166 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-3.89

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-12.08x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-141 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

1,300

The number of full time employees.

Revenue & Earnings

Balance Sheet

Invitae Corp.

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

News

Invitae CEO on how COVID-19 testing could have a positive impact on the future of genetics testing

Invitae CEO on how COVID-19 testing could have a positive impact on the future of genetics testing

Invitae CEO Sean George joins Yahoo Finance's on the move to talk about how Invitae is bringing genetic testing and information into mainstream discussions.

Yahoo Finance Yahoo Finance, 2 days ago
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide

Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide

SAN FRANCISCO , Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA ), a leading genetics company, today announced that on October 2, 2020 , it completed the transaction to bring ArcherDX,...

Benzinga Benzinga, 17 days ago
Invitae Appoints Kimber Lockhart to its Board of Directors

Invitae Appoints Kimber Lockhart to its Board of Directors

SAN FRANCISCO, Sept. 11, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Kimber Lockhart to its Board of Directors, eff...

PR Newswire PR Newswire, about 1 month ago